Sichuan Tianrunyuan Enterprise Management Co., Ltd., Pu Xiaoping, Wang Baocai, Li Weijun and Wang Xin completed the acquisition of 3.18% stake in Sichuan Luzhou Buchang Biological Pharmaceutical Co., Ltd. from Shandong Buchang Pharmaceuticals Co., Ltd..
December 30, 2021
Share
Sichuan Tianrunyuan Enterprise Management Co., Ltd., Pu Xiaoping, Wang Baocai, Li Weijun and Wang Xin agreed to acquire 3.18% stake in Sichuan Luzhou Buchang Biological Pharmaceutical Co., Ltd. from Shandong Buchang Pharmaceuticals Co., Ltd. (SHSE:603858) for CNY 14 million on August 27, 2021. Sichuan Tianrunyuan Enterprise Management Co., Ltd., Pu Xiaoping, Wang Baocai, Li Weijun and Wang Xin signed equity transfer agreement to acquire 3.18% stake in Sichuan Luzhou Buchang Biological Pharmaceutical Co., Ltd. from Shandong Buchang Pharmaceuticals Co., Ltd. on December 20, 2021. Sichuan Tianrunyuan Enterprise Management Co., Ltd. will acquire 2% stake for CNY 8.8 million, Pu Xiaoping will acquire 1% stake for CNY 4.4 million, Wang Baocai will acquire 0.09% stake for CNY 0.4 million, Li Weijun will acquire 0.045% stake for CNY 0.2 million and Li Weijun will acquire 0.045% stake for CNY 0.2 million. Sichuan Luzhou Buchang Biological Pharmaceutical Co., Ltd. reported total assets of CNY 1.203 billion and net assets of CNY 222.162 million as of May 31, 2021. The transaction has been approved by the Board of Shandong Buchang Pharmaceuticals Co., Ltd. Sichuan Tianrunyuan Enterprise Management Co., Ltd. completed the acquisition of 2% stake in Sichuan Luzhou Buchang Biological Pharmaceutical Co., Ltd. from Shandong Buchang Pharmaceuticals Co., Ltd. on December 21, 2021.
Sichuan Tianrunyuan Enterprise Management Co., Ltd., Pu Xiaoping, Wang Baocai, Li Weijun and Wang Xin completed the acquisition of 3.18% stake in Sichuan Luzhou Buchang Biological Pharmaceutical Co., Ltd. from Shandong Buchang Pharmaceuticals Co., Ltd. (SHSE:603858) on December 31, 2021.
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. is a China-based company principally engaged in the research, development, manufacture and distribution of Chinese patent medicines. The Companyâs main products are compound traditional Chinese medicines, including cerecarton capsules,wenxin granules, as well as danhong injections, among others. Its products are mainly applied to the fields of cardio-cerebrovascular diseases and gynecological diseases. The Company distributes its products within domestic market and to overseas markets, with North China, East China and Central China as its major markets.
Sichuan Tianrunyuan Enterprise Management Co., Ltd., Pu Xiaoping, Wang Baocai, Li Weijun and Wang Xin completed the acquisition of 3.18% stake in Sichuan Luzhou Buchang Biological Pharmaceutical Co., Ltd. from Shandong Buchang Pharmaceuticals Co., Ltd..
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. 
